| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 1,170 @ USD 463.86 | USD 542,716 | The ETF bought 1170 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 463.86 compared to the previous average buy price of 443.927. This is 4.5% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 4,032 @ USD 121.1 | USD 488,275 | The ETF bought 4032 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 121.1 compared to the previous average buy price of 117.748. This is 2.8% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 1,470 @ USD 326.1 | USD 479,367 | The ETF bought 1470 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 326.1 compared to the previous average buy price of 304.457. This is 7.1% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 483 @ USD 796.55 | USD 384,734 | The ETF bought 483 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 796.55 compared to the previous average buy price of 653.313. This is 21.9% higher than average price of previous purchases of REGN. |
| AZN - AstraZeneca PLC | BUY | 2,724 @ USD 94.65 | USD 257,827 | The ETF bought 2724 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 94.65 compared to the previous average buy price of 80.0485. This is 18.2% higher than average price of previous purchases of AZN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 618 @ USD 398.29 | USD 246,143 | The ETF bought 618 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 398.29 compared to the previous average buy price of 388.291. This is 2.6% higher than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 996 @ USD 175.97 | USD 175,266 | The ETF bought 996 new shares of INSM (Insmed Inc). The shares were bought for an average price of 175.97 compared to the previous average buy price of 143.356. This is 22.8% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 684 @ USD 187.62 | USD 128,332 | The ETF bought 684 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 187.62 compared to the previous average buy price of 150.332. This is 24.8% higher than average price of previous purchases of BIIB. |
| RVMD - Revolution Medicines Inc | BUY | 903 @ USD 118.64 | USD 107,132 | The ETF bought 903 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 118.64 compared to the previous average buy price of 51.1178. This is 132.1% higher than average price of previous purchases of RVMD. |
| ARGX - argenx NV ADR | BUY | 135 @ USD 788.49 | USD 106,446 | The ETF bought 135 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 788.49 compared to the previous average buy price of 721.699. This is 9.3% higher than average price of previous purchases of ARGX. |
| ILMN - Illumina Inc | BUY | 714 @ USD 141.07 | USD 100,724 | The ETF bought 714 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 141.07 compared to the previous average buy price of 106.449. This is 32.5% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 915 @ USD 106.87 | USD 97,786 | The ETF bought 915 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 106.87 compared to the previous average buy price of 82.1203. This is 30.1% higher than average price of previous purchases of INCY. |
| UTHR - United Therapeutics Corporation | BUY | 201 @ USD 483.23 | USD 97,129 | The ETF bought 201 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 483.23 compared to the previous average buy price of 385.114. This is 25.5% higher than average price of previous purchases of UTHR. |
| RPRX - Royalty Pharma Plc | BUY | 1,995 @ USD 40.17 | USD 80,139 | The ETF bought 1995 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 40.17 compared to the previous average buy price of 36.7735. This is 9.2% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 132 @ USD 595 | USD 78,540 | The ETF bought 132 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 595 compared to the previous average buy price of 448.714. This is 32.6% higher than average price of previous purchases of MEDP. |
| ROIV - Roivant Sciences Ltd | BUY | 3,246 @ USD 21.98 | USD 71,347 | The ETF bought 3246 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 21.98 compared to the previous average buy price of 15.445. This is 42.3% higher than average price of previous purchases of ROIV. |
| BBIO - BridgeBio Pharma Inc | BUY | 900 @ USD 77.25 | USD 69,525 | The ETF bought 900 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 77.25 compared to the previous average buy price of 52.7455. This is 46.5% higher than average price of previous purchases of BBIO. |
| VTRS - Viatris Inc | BUY | 5,376 @ USD 12.76 | USD 68,598 | The ETF bought 5376 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 12.76 compared to the previous average buy price of 9.98255. This is 27.8% higher than average price of previous purchases of VTRS. |
| SMMT - Summit Therapeutics PLC | BUY | 3,474 @ USD 19.68 | USD 68,368 | The ETF bought 3474 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 19.68 compared to the previous average buy price of 20.2728. This is -2.9% lower than average price of previous purchases of SMMT. |
| GH - Guardant Health Inc | BUY | 603 @ USD 110.17 | USD 66,433 | The ETF bought 603 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 110.17 compared to the previous average buy price of 69.7172. This is 58.0% higher than average price of previous purchases of GH. |
| NBIX - Neurocrine Biosciences Inc | BUY | 465 @ USD 135.79 | USD 63,142 | The ETF bought 465 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 135.79 compared to the previous average buy price of 135.854. This is 0.0% lower than average price of previous purchases of NBIX. |
| MRNA - Moderna Inc | BUY | 1,824 @ USD 34.3 | USD 62,563 | The ETF bought 1824 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 34.3 compared to the previous average buy price of 28.0975. This is 22.1% higher than average price of previous purchases of MRNA. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 756 @ USD 80.3 | USD 60,707 | The ETF bought 756 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 80.3 compared to the previous average buy price of 57.5882. This is 39.4% higher than average price of previous purchases of IONS. |
| SNY - Sanofi ADR | BUY | 1,236 @ USD 49.03 | USD 60,601 | The ETF bought 1236 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 49.03 compared to the previous average buy price of 49.8588. This is -1.7% lower than average price of previous purchases of SNY. |
| ASND - Ascendis Pharma AS | BUY | 288 @ USD 202.99 | USD 58,461 | The ETF bought 288 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 202.99 compared to the previous average buy price of 187.181. This is 8.4% higher than average price of previous purchases of ASND. |
| EXEL - Exelixis Inc | BUY | 1,251 @ USD 44.04 | USD 55,094 | The ETF bought 1251 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 44.04 compared to the previous average buy price of 41.7764. This is 5.4% higher than average price of previous purchases of EXEL. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 105 @ USD 514.06 | USD 53,976 | The ETF bought 105 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 514.06 compared to the previous average buy price of 416.745. This is 23.4% higher than average price of previous purchases of MDGL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 897 @ USD 58.95 | USD 52,878 | The ETF bought 897 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 58.95 compared to the previous average buy price of 57.0795. This is 3.3% higher than average price of previous purchases of BMRN. |
| RNA - Avidity Biosciences Inc | BUY | 702 @ USD 72.37 | USD 50,804 | The ETF bought 702 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.37 compared to the previous average buy price of 51.358. This is 40.9% higher than average price of previous purchases of RNA. |
| BNTX - BioNTech SE | BUY | 471 @ USD 99.85 | USD 47,029 | The ETF bought 471 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 99.85 compared to the previous average buy price of 102.791. This is -2.9% lower than average price of previous purchases of BNTX. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 285 @ USD 161.13 | USD 45,922 | The ETF bought 285 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 161.13 compared to the previous average buy price of 136.472. This is 18.1% higher than average price of previous purchases of JAZZ. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 633 @ USD 64.56 | USD 40,866 | The ETF bought 633 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 64.56 compared to the previous average buy price of 31.0898. This is 107.7% higher than average price of previous purchases of ARWR. |
| HALO - Halozyme Therapeutics Inc | BUY | 549 @ USD 72.47 | USD 39,786 | The ETF bought 549 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 72.47 compared to the previous average buy price of 61.8703. This is 17.1% higher than average price of previous purchases of HALO. |
| AXSM - Axsome Therapeutics Inc | BUY | 234 @ USD 169.38 | USD 39,635 | The ETF bought 234 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 169.38 compared to the previous average buy price of 124.759. This is 35.8% higher than average price of previous purchases of AXSM. |
| CYTK - Cytokinetics Inc | BUY | 570 @ USD 62.51 | USD 35,631 | The ETF bought 570 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 62.51 compared to the previous average buy price of 49.5129. This is 26.2% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 336 @ USD 105.05 | USD 35,297 | The ETF bought 336 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 105.05 compared to the previous average buy price of 89.2251. This is 17.7% higher than average price of previous purchases of NUVL. |
| KRYS - Krystal Biotech Inc | BUY | 135 @ USD 261.41 | USD 35,290 | The ETF bought 135 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 261.41 compared to the previous average buy price of 179.352. This is 45.8% higher than average price of previous purchases of KRYS. |
| PRAX - Praxis Precision Medicines Inc | BUY | 117 @ USD 288.45 | USD 33,749 | The ETF bought 117 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 288.45 compared to the previous average buy price of 128.431. This is 124.6% higher than average price of previous purchases of PRAX. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 312 @ USD 101.02 | USD 31,518 | The ETF bought 312 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 101.02 compared to the previous average buy price of 84.2811. This is 19.9% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 375 @ USD 77.53 | USD 29,074 | The ETF bought 375 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 77.53 compared to the previous average buy price of 61.7588. This is 25.5% higher than average price of previous purchases of PTCT. |
| PCVX - Vaxcyte Inc | BUY | 612 @ USD 46.05 | USD 28,183 | The ETF bought 612 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 46.05 compared to the previous average buy price of 45.278. This is 1.7% higher than average price of previous purchases of PCVX. |
| COGT - Cogent Biosciences Inc | BUY | 717 @ USD 35.35 | USD 25,346 | The ETF bought 717 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 35.35 compared to the previous average buy price of 20.3778. This is 73.5% higher than average price of previous purchases of COGT. |
| KYMR - Kymera Therapeutics Inc | BUY | 336 @ USD 74.77 | USD 25,123 | The ETF bought 336 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 74.77 compared to the previous average buy price of 53.1929. This is 40.6% higher than average price of previous purchases of KYMR. |
| CRSP - Crispr Therapeutics AG | BUY | 444 @ USD 53.84 | USD 23,905 | The ETF bought 444 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 53.84 compared to the previous average buy price of 53.248. This is 1.1% higher than average price of previous purchases of CRSP. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 444 @ USD 53.25 | USD 23,643 | The ETF bought 444 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 53.25 compared to the previous average buy price of 38.3436. This is 38.9% higher than average price of previous purchases of CRNX. |
| PTGX - Protagonist Therapeutics Inc | BUY | 291 @ USD 80.22 | USD 23,344 | The ETF bought 291 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 80.22 compared to the previous average buy price of 65.5029. This is 22.5% higher than average price of previous purchases of PTGX. |
| ALKS - Alkermes Plc | BUY | 771 @ USD 29.66 | USD 22,868 | The ETF bought 771 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 29.66 compared to the previous average buy price of 30.0387. This is -1.3% lower than average price of previous purchases of ALKS. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 312 @ USD 68.61 | USD 21,406 | The ETF bought 312 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 68.61 compared to the previous average buy price of 31.6799. This is 116.6% higher than average price of previous purchases of GPCR. |
| IMVT - Immunovant Inc | BUY | 819 @ USD 26.03 | USD 21,319 | The ETF bought 819 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 26.03 compared to the previous average buy price of 19.3352. This is 34.6% higher than average price of previous purchases of IMVT. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 789 @ USD 26.78 | USD 21,129 | The ETF bought 789 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.78 compared to the previous average buy price of 22.1908. This is 20.7% higher than average price of previous purchases of ACAD. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 240 @ USD 86.57 | USD 20,777 | The ETF bought 240 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 86.57 compared to the previous average buy price of 59.9202. This is 44.5% higher than average price of previous purchases of MIRM. |
| FOLD - Amicus Therapeutics Inc | BUY | 1,440 @ USD 14.28 | USD 20,563 | The ETF bought 1440 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.28 compared to the previous average buy price of 8.23286. This is 73.5% higher than average price of previous purchases of FOLD. |
| SRRK - Scholar Rock Holding Corp | BUY | 480 @ USD 42.18 | USD 20,246 | The ETF bought 480 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 42.18 compared to the previous average buy price of 37.0267. This is 13.9% higher than average price of previous purchases of SRRK. |
| ADMA - ADMA Biologics Inc | BUY | 1,113 @ USD 17.95 | USD 19,978 | The ETF bought 1113 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 17.95 compared to the previous average buy price of 17.8244. This is 0.7% higher than average price of previous purchases of ADMA. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 255 @ USD 77.99 | USD 19,887 | The ETF bought 255 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 77.99 compared to the previous average buy price of 57.05. This is 36.7% higher than average price of previous purchases of APGE. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 93 @ USD 206.65 | USD 19,218 | The ETF bought 93 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 206.65 compared to the previous average buy price of 150.522. This is 37.3% higher than average price of previous purchases of LGND. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,470 @ USD 12.96 | USD 19,051 | The ETF bought 1470 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.96 compared to the previous average buy price of 9.73491. This is 33.1% higher than average price of previous purchases of AMRX. |
| GRAL - GRAIL, LLC | BUY | 180 @ USD 100.1 | USD 18,018 | The ETF bought 180 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 100.1 compared to the previous average buy price of 65.1711. This is 53.6% higher than average price of previous purchases of GRAL. |
| ACLX - Arcellx Inc | BUY | 270 @ USD 66.27 | USD 17,893 | The ETF bought 270 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 66.27 compared to the previous average buy price of 72.0997. This is -8.1% lower than average price of previous purchases of ACLX. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 573 @ USD 28.22 | USD 16,170 | The ETF bought 573 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 28.22 compared to the previous average buy price of 20.4547. This is 38.0% higher than average price of previous purchases of ARQT. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 591 @ USD 27.3 | USD 16,134 | The ETF bought 591 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 27.3 compared to the previous average buy price of 21.2567. This is 28.4% higher than average price of previous purchases of APLS. |
| VCYT - Veracyte Inc | BUY | 369 @ USD 42.04 | USD 15,513 | The ETF bought 369 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 42.04 compared to the previous average buy price of 35.2994. This is 19.1% higher than average price of previous purchases of VCYT. |
| IDYA - Ideaya Biosciences Inc | BUY | 408 @ USD 37.38 | USD 15,251 | The ETF bought 408 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 37.38 compared to the previous average buy price of 26.4505. This is 41.3% higher than average price of previous purchases of IDYA. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 198 @ USD 76.87 | USD 15,220 | The ETF bought 198 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 76.87 compared to the previous average buy price of 57.4302. This is 33.8% higher than average price of previous purchases of TARS. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 360 @ USD 42.15 | USD 15,174 | The ETF bought 360 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.15 compared to the previous average buy price of 37.8339. This is 11.4% higher than average price of previous purchases of XENE. |
| TERN - Tern Plc | BUY | 420 @ USD 35.48 | USD 14,902 | The ETF bought 420 new shares of TERN (Tern Plc). The shares were bought for an average price of 35.48 compared to the previous average buy price of 12.1846. This is 191.2% higher than average price of previous purchases of TERN. |
| VERA - Vera Therapeutics Inc | BUY | 297 @ USD 48.71 | USD 14,467 | The ETF bought 297 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 48.71 compared to the previous average buy price of 30.7445. This is 58.4% higher than average price of previous purchases of VERA. |
| TVTX - Travere Therapeutics Inc | BUY | 417 @ USD 34.58 | USD 14,420 | The ETF bought 417 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 34.58 compared to the previous average buy price of 24.5956. This is 40.6% higher than average price of previous purchases of TVTX. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 267 @ USD 51.11 | USD 13,646 | The ETF bought 267 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 51.11 compared to the previous average buy price of 39.8208. This is 28.4% higher than average price of previous purchases of SUPN. |
| IRON - Ironveld Plc | BUY | 174 @ USD 78.14 | USD 13,596 | The ETF bought 174 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 78.14 compared to the previous average buy price of 66.5877. This is 17.3% higher than average price of previous purchases of IRON. |
| BEAM - Beam Therapeutics Inc | BUY | 474 @ USD 27.55 | USD 13,059 | The ETF bought 474 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 27.55 compared to the previous average buy price of 22.0619. This is 24.9% higher than average price of previous purchases of BEAM. |
| EWTX - Edgewise Therapeutics Inc | BUY | 495 @ USD 24.9 | USD 12,326 | The ETF bought 495 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 24.9 compared to the previous average buy price of 18.1415. This is 37.3% higher than average price of previous purchases of EWTX. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 369 @ USD 33.37 | USD 12,314 | The ETF bought 369 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 33.37 compared to the previous average buy price of 26.5062. This is 25.9% higher than average price of previous purchases of MLYS. |
| DYN - Dyne Therapeutics Inc | BUY | 669 @ USD 17.77 | USD 11,888 | The ETF bought 669 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 17.77 compared to the previous average buy price of 14.9731. This is 18.7% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 669 @ USD 17.77 | USD 11,888 | The ETF bought 669 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 17.77 compared to the previous average buy price of 14.9731. This is 18.7% higher than average price of previous purchases of DYN. |
| SRPT - Sarepta Therapeutics Inc | BUY | 498 @ USD 23.83 | USD 11,867 | The ETF bought 498 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 23.83 compared to the previous average buy price of 30.1358. This is -20.9% lower than average price of previous purchases of SRPT. |
| DNLI - Denali Therapeutics Inc | BUY | 687 @ USD 17.08 | USD 11,734 | The ETF bought 687 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 17.08 compared to the previous average buy price of 16.221. This is 5.3% higher than average price of previous purchases of DNLI. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 714 @ USD 15.76 | USD 11,253 | The ETF bought 714 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.76 compared to the previous average buy price of 13.5535. This is 16.3% higher than average price of previous purchases of ADPT. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 2,409 @ USD 4.66 | USD 11,226 | The ETF bought 2409 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.66 compared to the previous average buy price of 5.28621. This is -11.8% lower than average price of previous purchases of RXRX. |
| OCUL - Ocular Therapeutix Inc | BUY | 996 @ USD 11.26 | USD 11,215 | The ETF bought 996 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.26 compared to the previous average buy price of 11.0176. This is 2.2% higher than average price of previous purchases of OCUL. |
| SYRE - Spyre Therapeutics Inc. | BUY | 363 @ USD 30.61 | USD 11,111 | The ETF bought 363 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 30.61 compared to the previous average buy price of 24.7759. This is 23.5% higher than average price of previous purchases of SYRE. |
| TXG - 10X Genomics Inc | BUY | 543 @ USD 20.46 | USD 11,110 | The ETF bought 543 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 20.46 compared to the previous average buy price of 13.6816. This is 49.5% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 543 @ USD 20.46 | USD 11,110 | The ETF bought 543 new shares of TXG (Terex Corporation). The shares were bought for an average price of 20.46 compared to the previous average buy price of 13.6816. This is 49.5% higher than average price of previous purchases of TXG. |
| WVE - Wave Life Sciences Ltd | BUY | 783 @ USD 13.84 | USD 10,837 | The ETF bought 783 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 13.84 compared to the previous average buy price of 8.45127. This is 63.8% higher than average price of previous purchases of WVE. |
| IBRX - Immunitybio Inc | BUY | 4,611 @ USD 2.33 | USD 10,744 | The ETF bought 4611 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.33 compared to the previous average buy price of 2.62316. This is -11.2% lower than average price of previous purchases of IBRX. |
| HRMY - Harmony Biosciences Holdings | BUY | 270 @ USD 38.55 | USD 10,409 | The ETF bought 270 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 38.55 compared to the previous average buy price of 33.4766. This is 15.2% higher than average price of previous purchases of HRMY. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 366 @ USD 28.08 | USD 10,277 | The ETF bought 366 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 28.08 compared to the previous average buy price of 12.9837. This is 116.3% higher than average price of previous purchases of OLMA. |
| RARE - Ultragenyx | BUY | 450 @ USD 22.51 | USD 10,130 | The ETF bought 450 new shares of RARE (Ultragenyx). The shares were bought for an average price of 22.51 compared to the previous average buy price of 35.7764. This is -37.1% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 450 @ USD 22.51 | USD 10,130 | The ETF bought 450 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 22.51 compared to the previous average buy price of 35.7764. This is -37.1% lower than average price of previous purchases of RARE. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 450 @ USD 22.42 | USD 10,089 | The ETF bought 450 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 22.42 compared to the previous average buy price of 19.6605. This is 14.0% higher than average price of previous purchases of CNTA. |
| TWST - Twist Bioscience Corp | BUY | 285 @ USD 35.32 | USD 10,066 | The ETF bought 285 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 35.32 compared to the previous average buy price of 34.5878. This is 2.1% higher than average price of previous purchases of TWST. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 618 @ USD 15.15 | USD 9,363 | The ETF bought 618 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.15 compared to the previous average buy price of 11.4937. This is 31.8% higher than average price of previous purchases of AUPH. |
| GMAB - Genmab AS | BUY | 273 @ USD 34.26 | USD 9,353 | The ETF bought 273 new shares of GMAB (Genmab AS). The shares were bought for an average price of 34.26 compared to the previous average buy price of 28.319. This is 21.0% higher than average price of previous purchases of GMAB. |
| LEGN - Legend Biotech Corp | BUY | 393 @ USD 23.6 | USD 9,275 | The ETF bought 393 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 23.6 compared to the previous average buy price of 32.3615. This is -27.1% lower than average price of previous purchases of LEGN. |
| NRIX - Nurix Therapeutics Inc | BUY | 474 @ USD 19.3 | USD 9,148 | The ETF bought 474 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 19.3 compared to the previous average buy price of 14.7273. This is 31.0% higher than average price of previous purchases of NRIX. |
| VCEL - Vericel Corp Ord | BUY | 237 @ USD 38.56 | USD 9,139 | The ETF bought 237 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 38.56 compared to the previous average buy price of 39.8531. This is -3.2% lower than average price of previous purchases of VCEL. |
| ERAS - Erasca Inc | BUY | 1,329 @ USD 6.76 | USD 8,984 | The ETF bought 1329 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 6.76 compared to the previous average buy price of 2.08169. This is 224.7% higher than average price of previous purchases of ERAS. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 210 @ USD 42.67 | USD 8,961 | The ETF bought 210 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 42.67 compared to the previous average buy price of 33.0783. This is 29.0% higher than average price of previous purchases of KNSA. |
| ARDX - Ardelyx Inc | BUY | 1,140 @ USD 7.74 | USD 8,824 | The ETF bought 1140 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.74 compared to the previous average buy price of 4.95187. This is 56.3% higher than average price of previous purchases of ARDX. |
| STOK - Stoke Therapeutics Inc | BUY | 267 @ USD 32.85 | USD 8,771 | The ETF bought 267 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 32.85 compared to the previous average buy price of 20.085. This is 63.6% higher than average price of previous purchases of STOK. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 405 @ USD 21 | USD 8,505 | The ETF bought 405 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 21 compared to the previous average buy price of 14.2799. This is 47.1% higher than average price of previous purchases of SNDX. |
| DVAX - Dynavax Technologies Corporation | BUY | 549 @ USD 15.41 | USD 8,460 | The ETF bought 549 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.41 compared to the previous average buy price of 10.7234. This is 43.7% higher than average price of previous purchases of DVAX. |
| MNKD - MannKind Corp | BUY | 1,440 @ USD 5.85 | USD 8,424 | The ETF bought 1440 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.85 compared to the previous average buy price of 4.9905. This is 17.2% higher than average price of previous purchases of MNKD. |
| HROW - Harrow Health Inc | BUY | 174 @ USD 46.78 | USD 8,140 | The ETF bought 174 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 46.78 compared to the previous average buy price of 37.4355. This is 25.0% higher than average price of previous purchases of HROW. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 351 @ USD 23.17 | USD 8,133 | The ETF bought 351 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 23.17 compared to the previous average buy price of 17.6014. This is 31.6% higher than average price of previous purchases of ZYME. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 105 @ USD 76.28 | USD 8,009 | The ETF bought 105 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 76.28 compared to the previous average buy price of 75.859. This is 0.6% higher than average price of previous purchases of ANIP. |
| PHVS - Pharvaris BV | BUY | 300 @ USD 25.89 | USD 7,767 | The ETF bought 300 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 25.89 compared to the previous average buy price of 25.7075. This is 0.7% higher than average price of previous purchases of PHVS. |
| AGIO - Agios Pharm | BUY | 273 @ USD 28.41 | USD 7,756 | The ETF bought 273 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 28.41 compared to the previous average buy price of 33.7425. This is -15.8% lower than average price of previous purchases of AGIO. |
| PGEN - Precigen Inc | BUY | 1,659 @ USD 4.59 | USD 7,615 | The ETF bought 1659 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.59 compared to the previous average buy price of 3.01802. This is 52.1% higher than average price of previous purchases of PGEN. |
| NVCR - Novocure Ltd | BUY | 525 @ USD 14.35 | USD 7,534 | The ETF bought 525 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 14.35 compared to the previous average buy price of 15.4136. This is -6.9% lower than average price of previous purchases of NVCR. |
| FTRE - Fortrea Holdings Inc. | BUY | 432 @ USD 17.39 | USD 7,512 | The ETF bought 432 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 17.39 compared to the previous average buy price of 8.67303. This is 100.5% higher than average price of previous purchases of FTRE. |
| TNGX - Tango Therapeutics Inc | BUY | 630 @ USD 11.75 | USD 7,403 | The ETF bought 630 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 11.75 compared to the previous average buy price of 7.6617. This is 53.4% higher than average price of previous purchases of TNGX. |
| QURE - Uniqure NV | BUY | 291 @ USD 25.32 | USD 7,368 | The ETF bought 291 new shares of QURE (Uniqure NV). The shares were bought for an average price of 25.32 compared to the previous average buy price of 23.6675. This is 7.0% higher than average price of previous purchases of QURE. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 987 @ USD 7.4 | USD 7,304 | The ETF bought 987 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.4 compared to the previous average buy price of 8.0289. This is -7.8% lower than average price of previous purchases of BCRX. |
| ELVN - Enliven Therapeutics Inc. | BUY | 273 @ USD 26 | USD 7,098 | The ETF bought 273 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 26 compared to the previous average buy price of 20.8133. This is 24.9% higher than average price of previous purchases of ELVN. |
| INVA - Innoviva Inc | BUY | 351 @ USD 19.58 | USD 6,873 | The ETF bought 351 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.58 compared to the previous average buy price of 19.6896. This is -0.6% lower than average price of previous purchases of INVA. |
| IMCR - Immunocore Holdings Ltd | BUY | 204 @ USD 33 | USD 6,732 | The ETF bought 204 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 33 compared to the previous average buy price of 34.3214. This is -3.9% lower than average price of previous purchases of IMCR. |
| COLL - Collegium Pharmaceutical Inc | BUY | 147 @ USD 45.54 | USD 6,694 | The ETF bought 147 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.54 compared to the previous average buy price of 35.9572. This is 26.7% higher than average price of previous purchases of COLL. |
| RLAY - Relay Therapeutics Inc | BUY | 813 @ USD 7.99 | USD 6,496 | The ETF bought 813 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.99 compared to the previous average buy price of 4.97348. This is 60.7% higher than average price of previous purchases of RLAY. |
| TSHA - Taysha Gene Therapies Inc | BUY | 1,287 @ USD 4.98 | USD 6,409 | The ETF bought 1287 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.98 compared to the previous average buy price of 3.31154. This is 50.4% higher than average price of previous purchases of TSHA. |
| MNMD - Mind Medicine Inc | BUY | 462 @ USD 13.84 | USD 6,394 | The ETF bought 462 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 13.84 compared to the previous average buy price of 10.5253. This is 31.5% higher than average price of previous purchases of MNMD. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 516 @ USD 12.21 | USD 6,300 | The ETF bought 516 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 12.21 compared to the previous average buy price of 9.20962. This is 32.6% higher than average price of previous purchases of AMLX. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 777 @ USD 7.93 | USD 6,162 | The ETF bought 777 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.93 compared to the previous average buy price of 6.26657. This is 26.5% higher than average price of previous purchases of XERS. |
| ABCL - Abcellera Biologics Inc | BUY | 1,398 @ USD 4.37 | USD 6,109 | The ETF bought 1398 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 4.37 compared to the previous average buy price of 3.82582. This is 14.2% higher than average price of previous purchases of ABCL. |
| SPRY - Silverback Therapeutics Inc | BUY | 465 @ USD 13.06 | USD 6,073 | The ETF bought 465 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 13.06 compared to the previous average buy price of 12.2912. This is 6.3% higher than average price of previous purchases of SPRY. |
| AMPH - Amphastar P | BUY | 216 @ USD 27.74 | USD 5,992 | The ETF bought 216 new shares of AMPH (Amphastar P). The shares were bought for an average price of 27.74 compared to the previous average buy price of 25.9611. This is 6.9% higher than average price of previous purchases of AMPH. |
| ANAB - AnaptysBio Inc | BUY | 129 @ USD 44.67 | USD 5,762 | The ETF bought 129 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 44.67 compared to the previous average buy price of 28.8734. This is 54.7% higher than average price of previous purchases of ANAB. |
| SANA - Sana Biotechnology Inc | BUY | 1,245 @ USD 4.56 | USD 5,677 | The ETF bought 1245 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.56 compared to the previous average buy price of 3.50426. This is 30.1% higher than average price of previous purchases of SANA. |
| NTLA - Intellia Therapeutics Inc | BUY | 540 @ USD 10.38 | USD 5,605 | The ETF bought 540 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 10.38 compared to the previous average buy price of 11.4159. This is -9.1% lower than average price of previous purchases of NTLA. |
| SVRA - Savara Inc | BUY | 957 @ USD 5.81 | USD 5,560 | The ETF bought 957 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.81 compared to the previous average buy price of 4.27716. This is 35.8% higher than average price of previous purchases of SVRA. |
| NVAX - Novavax Inc | BUY | 762 @ USD 7.27 | USD 5,540 | The ETF bought 762 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 7.27 compared to the previous average buy price of 7.21915. This is 0.7% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 762 @ USD 7.27 | USD 5,540 | The ETF bought 762 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 7.27 compared to the previous average buy price of 7.21915. This is 0.7% higher than average price of previous purchases of NVAX. |
| GRFS - Grifols SA ADR | BUY | 573 @ USD 9.37 | USD 5,369 | The ETF bought 573 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.37 compared to the previous average buy price of 9.17695. This is 2.1% higher than average price of previous purchases of GRFS. |
| CSTL - Castle Biosciences Inc | BUY | 135 @ USD 39.34 | USD 5,311 | The ETF bought 135 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 39.34 compared to the previous average buy price of 26.7053. This is 47.3% higher than average price of previous purchases of CSTL. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 333 @ USD 15.015 | USD 5,000 | The ETF bought 333 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 15.015 compared to the previous average buy price of 10.7132. This is 40.2% higher than average price of previous purchases of PHAT. |
| PCRX - Pacira BioSciences, Inc. | BUY | 201 @ USD 23.53 | USD 4,730 | The ETF bought 201 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 23.53 compared to the previous average buy price of 23.9433. This is -1.7% lower than average price of previous purchases of PCRX. |
| XNCR - Xencor Inc | BUY | 336 @ USD 13.89 | USD 4,667 | The ETF bought 336 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 13.89 compared to the previous average buy price of 12.6614. This is 9.7% higher than average price of previous purchases of XNCR. |
| URGN - UroGen Pharma Ltd | BUY | 219 @ USD 21.25 | USD 4,654 | The ETF bought 219 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 21.25 compared to the previous average buy price of 17.0915. This is 24.3% higher than average price of previous purchases of URGN. |
| VTYX - Ventyx Biosciences Inc | BUY | 336 @ USD 13.81 | USD 4,640 | The ETF bought 336 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 13.81 compared to the previous average buy price of 11.2075. This is 23.2% higher than average price of previous purchases of VTYX. |
| TBPH - Theravance Biopharma Inc | BUY | 234 @ USD 19.04 | USD 4,455 | The ETF bought 234 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 19.04 compared to the previous average buy price of 13.6926. This is 39.1% higher than average price of previous purchases of TBPH. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,773 @ USD 2.45 | USD 4,344 | The ETF bought 1773 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.45 compared to the previous average buy price of 2.39832. This is 2.2% higher than average price of previous purchases of IOVA. |
| RAPT - RAPT Therapeutics Inc | BUY | 129 @ USD 33.62 | USD 4,337 | The ETF bought 129 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 33.62 compared to the previous average buy price of 32.5175. This is 3.4% higher than average price of previous purchases of RAPT. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 471 @ USD 8.94 | USD 4,211 | The ETF bought 471 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.94 compared to the previous average buy price of 7.76351. This is 15.2% higher than average price of previous purchases of DAWN. |
| ABUS - Arbutus Biopharma Corp | BUY | 906 @ USD 4.62 | USD 4,186 | The ETF bought 906 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.62 compared to the previous average buy price of 3.87265. This is 19.3% higher than average price of previous purchases of ABUS. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 447 @ USD 9.15 | USD 4,090 | The ETF bought 447 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 9.15 compared to the previous average buy price of 10.6689. This is -14.2% lower than average price of previous purchases of ORIC. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 237 @ USD 16.8 | USD 3,982 | The ETF bought 237 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 16.8 compared to the previous average buy price of 13.5734. This is 23.8% higher than average price of previous purchases of KALV. |
| GERN - Geron Corporation | BUY | 2,943 @ USD 1.34 | USD 3,944 | The ETF bought 2943 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.44394. This is -7.2% lower than average price of previous purchases of GERN. |
| JANX - Janux Therapeutics Inc | BUY | 276 @ USD 14.16 | USD 3,908 | The ETF bought 276 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 14.16 compared to the previous average buy price of 26.0915. This is -45.7% lower than average price of previous purchases of JANX. |
| PAHC - Phibro Animal Health Corporation | BUY | 99 @ USD 39.44 | USD 3,905 | The ETF bought 99 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 39.44 compared to the previous average buy price of 31.6414. This is 24.6% higher than average price of previous purchases of PAHC. |
| KURA - Kura Oncology Inc | BUY | 408 @ USD 9.41 | USD 3,839 | The ETF bought 408 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 9.41 compared to the previous average buy price of 8.35714. This is 12.6% higher than average price of previous purchases of KURA. |
| VIR - Vir Biotechnology Inc | BUY | 639 @ USD 5.85001 | USD 3,738 | The ETF bought 639 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.85001 compared to the previous average buy price of 5.93812. This is -1.5% lower than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 639 @ USD 5.85001 | USD 3,738 | The ETF bought 639 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.85001 compared to the previous average buy price of 5.93812. This is -1.5% lower than average price of previous purchases of VIR. |
| ARVN - Arvinas Inc | BUY | 303 @ USD 12.07 | USD 3,657 | The ETF bought 303 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.07 compared to the previous average buy price of 10.0002. This is 20.7% higher than average price of previous purchases of ARVN. |
| RGNX - Regenxbio Inc | BUY | 237 @ USD 14.59 | USD 3,458 | The ETF bought 237 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 14.59 compared to the previous average buy price of 10.1393. This is 43.9% higher than average price of previous purchases of RGNX. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 876 @ USD 3.94 | USD 3,451 | The ETF bought 876 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.94 compared to the previous average buy price of 3.86963. This is 1.8% higher than average price of previous purchases of PRME. |
| ZLAB - Zai Lab Ltd | BUY | 183 @ USD 18.55 | USD 3,395 | The ETF bought 183 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 18.55 compared to the previous average buy price of 30.8098. This is -39.8% lower than average price of previous purchases of ZLAB. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 768 @ USD 4.06 | USD 3,118 | The ETF bought 768 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 4.06 compared to the previous average buy price of 2.4088. This is 68.5% higher than average price of previous purchases of IRWD. |
| CGEM - Cullinan Oncology LLC | BUY | 273 @ USD 10.9 | USD 2,976 | The ETF bought 273 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.9 compared to the previous average buy price of 8.62738. This is 26.3% higher than average price of previous purchases of CGEM. |
| REPL - Replimune Group Inc | BUY | 369 @ USD 8.03 | USD 2,963 | The ETF bought 369 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 8.03 compared to the previous average buy price of 9.21296. This is -12.8% lower than average price of previous purchases of REPL. |
| PACB - Pacific Biosciences of California | BUY | 1,431 @ USD 1.94 | USD 2,776 | The ETF bought 1431 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 1.94 compared to the previous average buy price of 1.73256. This is 12.0% higher than average price of previous purchases of PACB. |
| KROS - Keros Therapeutics Inc | BUY | 144 @ USD 19.2 | USD 2,765 | The ETF bought 144 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 19.2 compared to the previous average buy price of 15.9161. This is 20.6% higher than average price of previous purchases of KROS. |
| MGTX - MeiraGTx Holdings PLC | BUY | 366 @ USD 7.41 | USD 2,712 | The ETF bought 366 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.41 compared to the previous average buy price of 7.42524. This is -0.2% lower than average price of previous purchases of MGTX. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 687 @ USD 3.93 | USD 2,700 | The ETF bought 687 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.93 compared to the previous average buy price of 2.95542. This is 33.0% higher than average price of previous purchases of MRVI. |
| PRTA - Prothena Corporation plc | BUY | 276 @ USD 9.19001 | USD 2,536 | The ETF bought 276 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 9.19001 compared to the previous average buy price of 9.51337. This is -3.4% lower than average price of previous purchases of PRTA. |
| FULC - Fulcrum Therapeutics Inc | BUY | 255 @ USD 9.84999 | USD 2,512 | The ETF bought 255 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 9.84999 compared to the previous average buy price of 10.555. This is -6.7% lower than average price of previous purchases of FULC. |
| LYEL - Lyell Immunopharma Inc | BUY | 96 @ USD 24.55 | USD 2,357 | The ETF bought 96 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 24.55 compared to the previous average buy price of 7.34934. This is 234.0% higher than average price of previous purchases of LYEL. |
| SIGA - SIGA Technologies Inc | BUY | 354 @ USD 6.61 | USD 2,340 | The ETF bought 354 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.61 compared to the previous average buy price of 6.62736. This is -0.3% lower than average price of previous purchases of SIGA. |
| GLPG - Galapagos NV ADR | BUY | 66 @ USD 33.11 | USD 2,185 | The ETF bought 66 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 33.11 compared to the previous average buy price of 29.7278. This is 11.4% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 66 @ USD 33.11 | USD 2,185 | The ETF bought 66 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 33.11 compared to the previous average buy price of 29.7278. This is 11.4% higher than average price of previous purchases of GLPG. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 279 @ USD 7.33001 | USD 2,045 | The ETF bought 279 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 7.33001 compared to the previous average buy price of 4.98124. This is 47.2% higher than average price of previous purchases of VNDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 540 @ USD 3.73 | USD 2,014 | The ETF bought 540 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.73 compared to the previous average buy price of 4.66305. This is -20.0% lower than average price of previous purchases of RCKT. |
| ALT - Altitude Group Plc | BUY | 498 @ USD 4.02 | USD 2,002 | The ETF bought 498 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.02 compared to the previous average buy price of 4.89903. This is -17.9% lower than average price of previous purchases of ALT. |
| ALLO - Allogene Therapeutics Inc | BUY | 1,119 @ USD 1.71 | USD 1,913 | The ETF bought 1119 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.71 compared to the previous average buy price of 1.35072. This is 26.6% higher than average price of previous purchases of ALLO. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 252 @ USD 7.5 | USD 1,890 | The ETF bought 252 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 7.5 compared to the previous average buy price of 7.8495. This is -4.5% lower than average price of previous purchases of FDMT. |
| AVXL - Anavex Life Sciences Corp | BUY | 435 @ USD 4.28 | USD 1,862 | The ETF bought 435 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.28 compared to the previous average buy price of 7.92718. This is -46.0% lower than average price of previous purchases of AVXL. |
| TRDA - Entrada Therapeutics Inc | BUY | 180 @ USD 10.02 | USD 1,804 | The ETF bought 180 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.02 compared to the previous average buy price of 8.30337. This is 20.7% higher than average price of previous purchases of TRDA. |
| EOLS - Evolus Inc | BUY | 309 @ USD 5.65 | USD 1,746 | The ETF bought 309 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 5.65 compared to the previous average buy price of 8.522. This is -33.7% lower than average price of previous purchases of EOLS. |
| ACIU - AC Immune Ltd | BUY | 510 @ USD 3.41 | USD 1,739 | The ETF bought 510 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.41 compared to the previous average buy price of 2.60081. This is 31.1% higher than average price of previous purchases of ACIU. |
| AUTL - Autolus Therapeutics Ltd | BUY | 906 @ USD 1.81 | USD 1,640 | The ETF bought 906 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.81 compared to the previous average buy price of 1.7298. This is 4.6% higher than average price of previous purchases of AUTL. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 240 @ USD 6.64 | USD 1,594 | The ETF bought 240 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.64 compared to the previous average buy price of 8.12985. This is -18.3% lower than average price of previous purchases of BCYC. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 429 @ USD 3.44999 | USD 1,480 | The ETF bought 429 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.44999 compared to the previous average buy price of 3.24417. This is 6.3% higher than average price of previous purchases of AVIR. |
| ACRS - Aclaris Therapeutics Inc | BUY | 522 @ USD 2.63999 | USD 1,378 | The ETF bought 522 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 2.63999 compared to the previous average buy price of 2.7847. This is -5.2% lower than average price of previous purchases of ACRS. |
| OABI - OmniAb Inc. | BUY | 636 @ USD 1.91 | USD 1,215 | The ETF bought 636 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.91 compared to the previous average buy price of 1.88467. This is 1.3% higher than average price of previous purchases of OABI. |
| VYGR - Voyager Therapeutics Inc | BUY | 267 @ USD 4.01999 | USD 1,073 | The ETF bought 267 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.01999 compared to the previous average buy price of 3.94983. This is 1.8% higher than average price of previous purchases of VYGR. |
| EDIT - Editas Medicine Inc | BUY | 498 @ USD 2.07 | USD 1,031 | The ETF bought 498 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.07 compared to the previous average buy price of 2.60199. This is -20.4% lower than average price of previous purchases of EDIT. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 147 @ USD 6.78 | USD 997 | The ETF bought 147 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.78 compared to the previous average buy price of 12.3934. This is -45.3% lower than average price of previous purchases of ARCT. |
| HUMA - Humacyte Inc | BUY | 846 @ USD 1.17 | USD 990 | The ETF bought 846 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.17 compared to the previous average buy price of 1.96618. This is -40.5% lower than average price of previous purchases of HUMA. |
| CABA - Cabaletta Bio Inc | BUY | 468 @ USD 2.10001 | USD 983 | The ETF bought 468 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 2.10001 compared to the previous average buy price of 2.16002. This is -2.8% lower than average price of previous purchases of CABA. |
| CRBU - Caribou Biosciences Inc | BUY | 456 @ USD 1.65999 | USD 757 | The ETF bought 456 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.65999 compared to the previous average buy price of 1.70747. This is -2.8% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 54.2 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 54.2. The average price that CGON shares were previous bought at was USD 33.3307. The current market price is 62.6% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 661,549 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2026-01-09 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-09 this would crystalise an overall loss. |